A Single-Institute Cross-sectional Study of HCV-Positive Cancer Patients’ Quality of Life in Egypt
DOI:
https://doi.org/10.3889/oamjms.2022.6404Keywords:
Quality of life, Oncology, Viral hepatitis, European Organization for Treatment of Cancer Quality of Life Questionnaire -C30 v3Abstract
BACKGROUND: Egypt is the country with the greatest number of hepatitis C virus (HCV) genotype 4 infections. The latest mass screening campaign in Egypt in 2018 reported an overall HCV seroprevalence of 4.61% (95% confidence interval 4.61 to 4.62) among the 48,345,948 subjects tested. The prevalence of HCV in the cancer population is estimated to range from 1.5 to 32%. HCV per se might directly influence health-related quality of life (HRQoL), via colonization of microglia in the brain or, indirectly, via the effect of systemic inflammatory cytokines which, in turn, can trigger brain interleukin production. Thus, there is an increased interest about the effect of the dual burden of HCV in cancer patients and its impact on the patients’’ HRQoL.
AIM: The study is conducted at the outpatient chemotherapy unit of a university hospital in Egypt, over a period of 6 months to estimate their quality of life (QoL) scores according to the European Organization for Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 v3.
MATERIALS AND METHODS: A cross-sectional study was conducted, including all patients referred to the chemotherapy clinic during the study period and proven to be HCV positive. Recruited patients were asked to fill the EORTC QLQ-C30 v3 questionnaire, and data regarding their medical conditions were collected from their medical files.
RESULTS: One hundred and sixteen (8.8%) patients were HCV positive. QoL scores were statistically significantly lower from almost all reference values categories published in the EORTC manual.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Samiei Siboni F, Alimoradi Z, Atashi V, Alipour M, Khatooni M. Quality of life in different chronic diseases and its related factors. Int J Prev Med. 2019;10:65. https://doi.org/10.4103/ijpvm.IJPVM_429_17 PMid:31198500 DOI: https://doi.org/10.4103/ijpvm.IJPVM_429_17
Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016;14:52. https://doi.org10.1186/s12955-016-0449-z PMid:27016084 DOI: https://doi.org/10.1186/s12955-016-0449-z
Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol. 2014;20(11):2771-6. https://doi.org/10.3748/wjg.v20.i11.2771 PMid:24659870 DOI: https://doi.org/10.3748/wjg.v20.i11.2771
Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med. 2020;382(12):1166-74. https://doi.org/10.1056/NEJMsr1912628 PMid:32187475 DOI: https://doi.org/10.1056/NEJMsr1912628
El-Zanaty F, Way A. Egyptian Demographic Health Survey. Cairo, Egypt: El-Zanaty and Associates, and Macro International; 2009.
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: Results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. https://doi.org/10.1155/2014/437971 PMid:25328522 DOI: https://doi.org/10.1155/2014/437971
Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, et al. Oncologic implications of chronic hepatitis C virus infection. J Oncol Pract. 2019;15(12):629-37. https://doi.org/10.1200/JOP.19.00370 PMid:31825756 DOI: https://doi.org/10.1200/JOP.19.00370
Veilkova G, Bottomly A. Looking Back at 30 Years of Progress from Methodological Developments to Making a Real Impact on Oncology Practice. Belgium: European Organization for Research and Treatment of Cancer QL Newsletter: 2012. p. 2. DOI: https://doi.org/10.1016/S1359-6349(12)70023-X
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76. https://doi.org/10.1093/jnci/85.5.365 PMid:8433390 DOI: https://doi.org/10.1093/jnci/85.5.365
Scott, NW, Fayers PM, Aaronson NK, Bottomley A, Koller M, Groenvold M, et al. EORTC QLQ-C30 Reference Values. Belgium: European Organisation for Research and Treatment of Cancer; 2008.
Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, et al. Prevalence of hepatitis B virus, hepatitis C virus, and HIV infection among patients with newly diagnosed cancer from academic and community oncology practices. JAMA Oncol. 2019;5(4):497-505. https://doi.org/10.1001/jamaoncol.2018.6437 PMid:30653226 DOI: https://doi.org/10.1001/jamaoncol.2018.6437
Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of HEPATITIS C virus infection in the United States 2013-2016. Hepatology. 2019;69(3):1020-31. https://doi.org/10.1002/hep.30297 PMid:30398671 DOI: https://doi.org/10.1002/hep.30297
Abd El-Wahab EA. Health-related quality of life among chronic HCV patients: Measuring disease and treatment response impacts. Ann Trop med Public Health. 2016;9:152-8. https://doi.org/10.4103/1755-6783.181656 DOI: https://doi.org/10.4103/1755-6783.181656
Dehkordi A, Heydarnejad MS, Fatehi D. Quality of life in cancer patients undergoing chemotherapy. Oman Med J. 2009;24(3):204-7. https://doi.org/10.5001/omj.2009.40 PMid:22224186 DOI: https://doi.org/10.5001/omj.2009.40
Downloads
Published
How to Cite
License
Copyright (c) 2022 Noha Hayek, Mona El Lawindi, Hanan Ali Sayed (Author); Amal Sedrak; Zeinab M. Abd. El Hafeez, Amr Shafik Saad (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
